Luxembourg 7/31/17—Testing firm Eurofins Scientific has agreed to acquire DiscoverX for an undisclosed amount. DiscoverX provides products and services for drug discovery, including reagents, cell-based assay kits and screening services. The company’s Enzyme Fragment Complementation (EFC) technology is used for GPCR screening. DiscoverX has 137 employees at four locations. “DiscoverX adds another spectrum of new advanced services that Eurofins can now offer to its clients,” commented Eurofins CEO Dr. Gilles Martin. “This transaction is another demonstration of Eurofins’ commitment to provide the most comprehensive portfolio of laboratory services in the discovery pharmacology field which enjoys a strong outsourcing growth trend.” The deal is expected to be completed in the coming weeks.

DiscoverX’s service business fits with Eurofins’ Pharma Discovery Services businesses. Eurofins is one of the world’s largest contract testing companies, recording 2016 revenues of more than $2 billion (see IBO 7/15/17). Eurofins’ offering of laboratory products is minimal, primarily being oligonucleotides.